Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Exenatide, a GLP-1 agonist sold under the brand names Byetta and Bydureon by AstraZeneca (LSE: AZN) as a type 2 diabetes drug, could be useful in another indication, a trial has found
Many patients report that the financial savings make compounded versions their only feasible option for ongoing treatment
While Novo Nordisk and Eli Lilly both have promising GLP-1 pipelines and anticipate multiple drug launches over the next five years, several other big pharma companies are also investing heavily in GLP-1 drugs in a bid to grab a slice of the pie, primarily through the acquisition of biotech developers [FIGURE THREE]
Licensed weight management treatments include Wegovy (semaglutide) and Mounjaro (tirzepatide)
US$ 28.60
US$ 26.87
US$ 29.76
US$ 25.59
